These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 31854307)

  • 1. Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.
    Yüzbaşıoğlu B; Ustaoğlu M; Yüzbaşıoğlu Ş; Akbulut UE; Özdil K
    Turk J Gastroenterol; 2019 Dec; 30(12):1025-1029. PubMed ID: 31854307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu İ; Ersoz HO
    Endocrine; 2009 Dec; 36(3):473-8. PubMed ID: 19859836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism.
    Erem C; Ucuncu O; Yilmaz M; Kocak M; Nuhoglu I; Ersoz HO
    Endocrine; 2009 Feb; 35(1):75-80. PubMed ID: 18958631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism.
    Alioğlu B; Kılıç N; Şimşek E; Dallar Y
    J Clin Res Pediatr Endocrinol; 2012 Sep; 4(3):146-50. PubMed ID: 22985614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
    J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
    Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
    Bladbjerg EM; Madsen JS; Kristensen SR; Abrahamsen B; Brixen K; Mosekilde L; Jespersen J
    J Thromb Haemost; 2003 Jun; 1(6):1208-14. PubMed ID: 12871321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system.
    Danese S; Papa A
    Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):826-8. PubMed ID: 18794594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
    Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
    Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
    Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor and thrombin-activatable carboxypeptidase B for prediction of early atherosclerosis in gouty arthritis.
    Uyanik MS; Pamuk GE; Pamuk ON; Tuncel SA
    Thromb Res; 2014 Aug; 134(2):526-30. PubMed ID: 24974054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer.
    Koldas M; Gummus M; Seker M; Seval H; Hulya K; Dane F; Kural A; Gumus A; Salepci T; Turhal NS
    Clin Lung Cancer; 2008 Mar; 9(2):112-5. PubMed ID: 18501098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in acromegaly patients in remission.
    Erdoğan M; Özbek M; Akbal E; Üreten K
    Turk J Med Sci; 2019 Oct; 49(5):1381-1385. PubMed ID: 31549496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
    Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
    Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis.
    Beyazit Y; Sayilir A; Tanoglu A; Kekilli M; Kocak E; Ekiz F; Tas A
    Intern Med; 2016; 55(14):1831-6. PubMed ID: 27432089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor pathway inhibitor and thrombin activatable fibrinolytic inhibitor plasma levels following burn and septic injuries in rats.
    Ravindranath TM; Goto M; Demir M; Tobu M; Kujawski MF; Hoppensteadt D; Samonte V; Iqbal O; Sayeed MM; Fareed J
    Clin Appl Thromb Hemost; 2004 Oct; 10(4):379-85. PubMed ID: 15497025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis.
    Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D
    Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis.
    Cetinkalp S; Tobu M; Karadeniz M; Buyukkeçeci F; Yilmaz C
    Intern Med; 2009; 48(5):281-5. PubMed ID: 19252348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of tissue factor pathway inhibitor in patients with inflammatory bowel disease.
    Cibor D; Szczeklik K; Mach T; Owczarek D
    Pol Arch Intern Med; 2019 Apr; 129(4):253-258. PubMed ID: 31038478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.